康方生物-B(09926.HK):採納2021年受限制股份單位計劃
格隆匯12月7日丨康方生物-B(09926.HK)宣佈,於2021年12月6日,董事會已議決採納2021年受限制股份單位計劃,以表彰若干合資格參與者的貢獻並向彼等提供獎勵,以挽留彼等協助集團持續經營及發展,並吸引合適人員推動集團進一步發展。
董事會根據2021年受限制股份單位計劃授出的受限制股份單位所涉及獎勵股份的最高數目(i)不得超過信託期內公司不時已發行股本總額的10%;及(ii)須受限於公司於有關時間已發行股本總額3%的年度上限。於任何12個月期間,根據該計劃可授予選定參與者的受限制股份單位相關獎勵股份的最高數目不得超過公司已發行股本的1%。就計算限額而言,根據該計劃條款失效的獎勵不得計算在內。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.